{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:17:16Z","timestamp":1791353836396,"version":"4.3.1"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.biopha.2017.09.059","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T13:47:53Z","timestamp":1505742473000},"page":"1209-1218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":292,"special_numbering":"C","title":["A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer"],"prefix":"10.1016","volume":"95","author":[{"given":"Ayman","family":"Shafei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam","family":"El-Bakly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sobhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Wagdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Aboelenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Marzouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"El Habak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ellithy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2017.09.059_bib0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.7314\/APJCP.2016.17.S3.43","article-title":"Incidence and mortality and epidemiology of breast cancer in the world","volume":"17","author":"Ghoncheh","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.biopha.2017.09.059_bib0010","doi-asserted-by":"crossref","first-page":"437971","DOI":"10.1155\/2014\/437971","article-title":"Cancer incidence in egypt: results of the national population-based cancer registry program","volume":"2014","author":"Ibrahim","year":"2014","journal-title":"J. Cancer Epidemiol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0015","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell\u2013derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2017.09.059_bib0020","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","article-title":"Prognostic and predictive factors in early-stage breast cancer","volume":"9","author":"Cianfrocca","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2017.09.059_bib0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1524-4741.2002.08002.x","article-title":"Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease 831","volume":"8","author":"Rivera","year":"2002","journal-title":"Breast J."},{"key":"10.1016\/j.biopha.2017.09.059_bib0030","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/djq029","article-title":"International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?","volume":"102","author":"Pagani","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2017.09.059_bib0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4155\/tde.10.24","article-title":"Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects","volume":"1","author":"Wang","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.biopha.2017.09.059_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133569","article-title":"Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials","volume":"10","author":"Xing","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2017.09.059_bib0045","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2478\/v10102-010-0036-9","article-title":"The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells","volume":"1","author":"Poljakov\u00e1","year":"2008","journal-title":"Interdiscip. Toxicol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0050","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.biopha.2017.09.059_bib0055","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.yjmcc.2006.06.009","article-title":"New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics","volume":"41","author":"Tokarska-Schlattner","year":"2006","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3727\/096504003108748294","article-title":"Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase","volume":"13","author":"Paw\u0142owska","year":"2003","journal-title":"Oncol. Res."},{"key":"10.1016\/j.biopha.2017.09.059_bib0065","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0070","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pcad.2006.10.002","article-title":"Doxorubicin-induced cardiomyopathy. from the cardiotoxic mechanisms to management","volume":"49","author":"Takemura","year":"2007","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.biopha.2017.09.059_bib0075","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"von Hoff","year":"1979","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2017.09.059_bib0080","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJM199506293322602","article-title":"Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer","volume":"332","author":"Lipshultz","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2017.09.059_bib0085","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"issue":"Suppl. 4","key":"10.1016\/j.biopha.2017.09.059_bib0090","first-page":"1","article-title":"Anthracyclines in the treatment of cancer. An overview","volume":"54","author":"Hortobagyi","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2017.09.059_bib0095","first-page":"670","article-title":"The anthracyclines: will we ever find a better doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc1566","article-title":"Cancer nanotechnology: opportunities and challenges","volume":"5","author":"Ferrari","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0105","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s11095-006-0284-8","article-title":"Nanotechnology: intelligent design to treat complex disease","volume":"23","author":"Couvreur","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2017.09.059_bib0110","first-page":"12","article-title":"Liposomal Doxorubicin in the treatment of breast cancer patients: a review","author":"Lao","year":"2013","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.biopha.2017.09.059_bib0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/btm2.10003","article-title":"Nanoparticles in the clinic","volume":"1","author":"Anselmo","year":"2016","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.biopha.2017.09.059_bib0120","first-page":"2885","article-title":"The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR)","volume":"19","author":"Krishna","year":"1999","journal-title":"Anticancer Res."},{"key":"10.1016\/j.biopha.2017.09.059_bib0125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.0.CO;2-1","article-title":"Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes","volume":"86","author":"Symon","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0130","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.2217\/nnm.13.118","article-title":"Current trends in the use of liposomes for tumor targeting","volume":"8","author":"Deshpande","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2017.09.059_bib0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijpharm.2009.03.018","article-title":"Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes","volume":"374","author":"Gao","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2017.09.059_bib0140","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.1124","article-title":"Predictive factors for the severity of congestive heart failure after an epirubicin-based treatment for metastatic breast cancer","author":"Ryberg","year":"2010","journal-title":"J. Clin. Oncol. Conference"},{"key":"10.1016\/j.biopha.2017.09.059_bib0145","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2017.09.059_bib0150","doi-asserted-by":"crossref","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","article-title":"Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer","volume":"24","author":"Jones","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0155","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2017.09.059_bib0160","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX???\/Doxil??) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0165","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0170","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0175","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/annonc\/mdh393","article-title":"Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer","volume":"15","author":"Chan","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0180","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1200\/JCO.2008.20.5013","article-title":"Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracyclin","volume":"27","author":"Sparano","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0185","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000093005","article-title":"Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40mg\/m2 every 4 weeks in previously treated patients with metastatic breast cancer","volume":"70","author":"Al-Batran","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.biopha.2017.09.059_bib0190","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/sj.bjc.6603158","article-title":"The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial","volume":"94","author":"Al-Batran","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0195","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3816\/CBC.2004.n.041","article-title":"Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure","volume":"5","author":"Martin","year":"2004","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0200","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s00280-006-0236-3","article-title":"Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study","volume":"58","author":"Ardavanis","year":"2006","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0205","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.coc.0000251400.47711.fe","article-title":"A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer","volume":"30","author":"Chow","year":"2007","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0210","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1080\/02841860600897868","article-title":"Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer","volume":"46","author":"Ulrich-Pur","year":"2007","journal-title":"Acta Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0215","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3816\/CBC.2007.n.028","article-title":"Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer","volume":"7","author":"Andreopoulou","year":"2007","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0220","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1200\/JCO.2009.22.7504","article-title":"Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines","volume":"27","author":"Trudeau","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0225","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3816\/CBC.2010.n.061","article-title":"Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer","volume":"10","author":"Irvin","year":"2010","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0230","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome)","volume":"18","author":"Lorusso","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0235","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/cncr.20983","article-title":"Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy","volume":"103","author":"Caggiano","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0240","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/COC.0b013e318165c01d","article-title":"Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model","volume":"31","author":"Dranitsaris","year":"2008","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2017.09.059_bib0245","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6601856","article-title":"Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP 1049C) in patients with advanced cancer","author":"Danson","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0250","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/sj.bjc.6602204","article-title":"Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin","volume":"91","author":"Matsumura","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0255","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1349-7006.2002.tb01217.x","article-title":"Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil)","volume":"93","author":"Tsukioka","year":"2002","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.biopha.2017.09.059_bib0260","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s10637-011-9709-2","article-title":"Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer","volume":"30","author":"Kato","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.biopha.2017.09.059_bib0265","first-page":"83","article-title":"Phase I clinical and pharmacokinetic study of PK1 [N \u2013 (2- hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic","volume":"5","author":"Vasey","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2017.09.059_bib0270","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1002\/anie.200462960","article-title":"Polymer therapeutics designed for a combination therapy of hormone-dependent cancer","volume":"44","author":"Vicent","year":"2005","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2017.09.059_bib0275","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1021\/bm060906i","article-title":"Synthesis of alginic acid-poly[2-(diethylamino)ethyl methacrylate] monodispersed nanoparticles by a polymer-monomer pair reaction system","volume":"8","author":"Guo","year":"2007","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biopha.2017.09.059_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/686108","article-title":"Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment","volume":"2012","author":"Abbasi","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.biopha.2017.09.059_bib0285","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3390\/ijms12031672","article-title":"Preliminary study of conformation and drug release mechanism of doxorubicin-conjugated glycol chitosan, via cis-aconityl linkage, by molecular modeling","volume":"12","author":"Srinophakun","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2017.09.059_bib0290","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1248\/cpb.58.1423","article-title":"Chitosan nanoparticles a promising system in novel drug delivery","volume":"58","author":"Nagpal","year":"2010","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.biopha.2017.09.059_bib0295","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/app.26038","article-title":"Preparation of nanoparticles composed of chitosan and its derivatives as delivery systems for macromolecules","volume":"105","author":"Sun","year":"2007","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.biopha.2017.09.059_bib0300","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.nano.2007.08.002","article-title":"Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin","volume":"3","author":"Zhang","year":"2007","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2017.09.059_bib0305","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.carbpol.2011.01.037","article-title":"Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin","volume":"84","author":"Ying","year":"2011","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.biopha.2017.09.059_bib0310","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jconrel.2011.12.021","article-title":"Administration, distribution, metabolism and elimination of polymer therapeutics","volume":"161","author":"Markovsky","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.biopha.2017.09.059_bib0315","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0169-409X(02)00047-9","article-title":"Pluronic?? block copolymers for overcoming drug resistance in cancer","volume":"54","author":"Kabanov","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2017.09.059_bib0320","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1054\/bjoc.2001.2165","article-title":"Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion","volume":"85","author":"Batrakova","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2017.09.059_bib0325","first-page":"4516","article-title":"Hyaluronan receptors are expressed on human malignant mesothelioma cells but not on normal mesothelial cells","volume":"54","author":"Asplund","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2017.09.059_bib0330","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0959-8049(96)00512-6","article-title":"High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival","volume":"33","author":"Dietrich","year":"1997","journal-title":"Eur. J. Cancer Part A"},{"key":"10.1016\/j.biopha.2017.09.059_bib0335","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1016\/j.biomaterials.2008.05.016","article-title":"Doxorubicin conjugated to d-??-tocopheryl polyethyleneglycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation","volume":"29","author":"Cao","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2017.09.059_bib0340","first-page":"465","article-title":"Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine a in healthy dogs","volume":"3","author":"Fischer","year":"2002","journal-title":"Vet. Ther."},{"key":"10.1016\/j.biopha.2017.09.059_bib0345","doi-asserted-by":"crossref","first-page":"20867","DOI":"10.1038\/srep20867","article-title":"Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles","volume":"6","author":"Rodzinski","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2017.09.059_bib0350","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/aic.12373","article-title":"Acid-sensitive magnetic nanoparticles as potential drug depots","volume":"57","author":"Wuang","year":"2011","journal-title":"AIChE J."},{"key":"10.1016\/j.biopha.2017.09.059_bib0355","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/02656730500158360","article-title":"Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique","volume":"21","author":"Johannsen","year":"2005","journal-title":"Int. J. Hyperthermia"},{"key":"10.1016\/j.biopha.2017.09.059_bib0360","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1006\/jsre.2000.6030","article-title":"Clinical applications of magnetic drug targeting","volume":"95","author":"L\u00fcbbe","year":"2001","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.biopha.2017.09.059_bib0365","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.addr.2012.09.031","article-title":"Multifunctional nanocarriers","volume":"64","author":"Torchilin","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2017.09.059_bib0370","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.07.006","article-title":"Novel method of doxorubicin-SPION reversible association for magnetic drug targeting","volume":"363","author":"Munnier","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2017.09.059_bib0375","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2011.06.010","article-title":"A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting","author":"Gautier","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2017.09.059_bib0380","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2015.10.020","article-title":"Bovine milk-derived exosomes for drug delivery","volume":"371","author":"Munagala","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2017.09.059_bib0385","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.biomaterials.2013.11.083","article-title":"A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy","volume":"35","author":"Tian","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2017.09.059_bib0390","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/02656736.2015.1036384","article-title":"Increased anti-tumour activity by exosomes derived from doxorubicin-treated tumour cells via heat stress","volume":"31","author":"Yang","year":"2015","journal-title":"Int. J. Hyperthermia"},{"key":"10.1016\/j.biopha.2017.09.059_bib0395","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.2217\/nnm.15.118","article-title":"Exosomal doxorubicin reduces the cardiac toxicity of doxorubicin","volume":"10","author":"Toffoli","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2017.09.059_bib0400","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.2217\/nnm-2016-0154","article-title":"Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models","volume":"11","author":"Hadla","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2017.09.059_bib0405","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0014-5793(03)01085-8","article-title":"Multidrug resistance ABC transporters","author":"Chang","year":"2003","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2017.09.059_bib0410","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","article-title":"Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance","volume":"358","author":"Kareva","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2017.09.059_bib0415","doi-asserted-by":"crossref","first-page":"21459","DOI":"10.1038\/srep21459","article-title":"A nanoparticulate pre-chemosensitizer for efficacious chemotherapy of multidrug resistant breast cancer","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2017.09.059_bib0420","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1517\/17425247.2015.960920","article-title":"Overcoming multidrug resistance with nanomedicines","volume":"12","author":"Ganoth","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2017.09.059_bib0425","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.nano.2013.07.005","article-title":"Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents","volume":"10","author":"Schell","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2017.09.059_bib0430","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/1061186021000072447","article-title":"Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models","volume":"10","author":"Gabizon","year":"2002","journal-title":"J. Drug Target."},{"key":"10.1016\/j.biopha.2017.09.059_bib0435","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(00)02528-9","article-title":"Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis","volume":"356","author":"Buyse","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2017.09.059_bib0440","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S1470-2045(06)70800-2","article-title":"Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis","volume":"7","author":"Johnson","year":"2006","journal-title":"Lancet Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217330998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332217330998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T08:04:34Z","timestamp":1771401874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332217330998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":88,"alternative-id":["S0753332217330998"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2017.09.059","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2017.09.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}